ADC Therapeutics SA
ADCT Real Time Price USDRecent trades of ADCT by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ADCT's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Anti-il13rα2 antibodies May. 07, 2024
-
Patent Title: Combination therapy with an anti-cd25 antibody-drug conjugate Mar. 07, 2023
-
Patent Title: Dosage regimes for the administration of an anti-cd25 adc Aug. 30, 2022
-
Patent Title: Pyrrolobenzodiazepine-antibody conjugates Jul. 12, 2022
-
Patent Title: Dosage regimes for the administration of an anti-cd19 adc May. 03, 2022
-
Patent Title: Pyrrolobenzodiazepine-antibody conjugates Nov. 02, 2021
-
Patent Title: Method for treating breast cancer Aug. 10, 2021
-
Patent Title: Pyrrolobenzodiazepine-antibody conjugates Oct. 13, 2020
-
Patent Title: Pyrrolobenzodiazepine-antibody conjugates Sep. 22, 2020
-
Patent Title: Pyrrolobenzodiazepine-anti-cd22 antibody conjugates Jul. 28, 2020
-
Patent Title: Combination therapy with an anti-axl antibody-drug conjugate Jan. 28, 2020
-
Patent Title: Pyrrolobenzodiazepine-anti-cd22 antibody conjugates Mar. 20, 2018
-
Patent Title: Anti-kidney associated antigen 1 (kaag1) antibodies Jan. 02, 2018
-
Patent Title: Antibodies against kidney associated antigen 1 and antigen binding fragments thereof Nov. 28, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of ADCT in WallStreetBets Daily Discussion
Recent insights relating to ADCT
Recent picks made for ADCT stock on CNBC
ETFs with the largest estimated holdings in ADCT
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ADCT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.